Welcome I have to share my excitement and enthusiasm with you!
Our flagship publication, Genetic Engineering & Biotechnology News (GEN), has been the most widely read publication in biotechnology since its inception 39 years ago. This year, we’ve expanded its content to include genome editing, one of the most important areas in biomedical research today and the latest iteration of the core technology on which GEN was founded. Complementing the latest coverage of drug discovery, omics, translational medicine, and bioprocessing, we continue to provide our readers with exclusive coverage of the technology products and people driving the field.
Academic institutions need to understand the technologies and have the information that can foster collaborations, especially as federal funding is so precarious. GEN’s companion publication, Clinical OMICS, provides in-depth coverage of advances in molecular diagnosis and personalized medicine, and is the only publication in the field with a sole focus on critical clinical applications. Taken together, these two publications are important for the academic community to foster research advances and applications. If you don’t already have a subscription, please contact us — we don’t want you to miss a single issue!
I’m feeling bold, and this year we are launching Death Research: The Last Frontier. Think about the importance and benefits of organ and cell transplantation, postmortem research, advances in resuscitation, and the fact that cells and brains are still alive after death is pronounced. This journal has been on my mind for many years since I first spoke about it with the late Nobel Prize Laureate, Francis Crick, who was then devoting all of his time to consciousness research. He thought it could be intriguing but that the time wasn’t right. It is now. As I have delved deep into this idea with scientific colleagues and others, I was amazed at how many people fear death, not the just the process of dying, but of the completely unknown. We continue to explore the earth, the solar system and space, and the seas, so I think of this as the “final frontier” of scholarly exploration. The Journal will be peer-reviewed, and reanimation, brain function, gene expression, and cryopreservation will be within its purview. It will be a challenging endeavor, but the journals I create have always been so.
Be sure The CRISPR Journal is among your holdings The promise and the perils of gene editing are enormous, and this, with over 70,000 downloads to date, is already the journal of record.
We hope you have added Autism in Adulthood to your collection for 2019. It is a growing issue and needs to be recognized and planned for as parents of adult children may not be around to take care of autistic adults throughout their lives.
Here in the US, we are all so grateful that the shutdown is over! We sent lunch to our local airport’s controllers. Local newspapers wrote about that, and then others did the same, which was terrific. I love making a difference in every way I can.
Yours 24/7,
Mary Ann
Founder, President, and CEO |
